Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer

C. Allison Stewart, Pan Tong, Robert J. Cardnell, Triparna Sen, Lerong Li, Carl M. Gay, Fatemah Masrorpour, You Fan, Rasha O. Bara, Ying Feng, Yuanbin Ru, Junya Fujimoto, Samrat T. Kundu, Leonard E. Post, Karen Yu, Yuqiao Shen, Bonnie S. Glisson, Ignacio Wistuba, John V. Heymach, Don L. GibbonsJing Wang, Lauren Averett Byers

Research output: Contribution to journalArticlepeer-review

145 Scopus citations

Abstract

Small cell lung cancer (SCLC) is one of the most aggressive forms of cancer, with a 5-year survival < 7%. A major barrier to progress is the absence of predictive biomarkers for chemotherapy and novel targeted agents such as PARP inhibitors. Using a high-throughput, integrated proteomic, transcriptomic, and genomic analysis of SCLC patient-derived xenografts (PDXs) and profiled cell lines, we identified biomarkers of drug sensitivity and determined their prevalence in patient tumors. In contrast to breast and ovarian cancer, PARP inhibitor response was not associated with mutations in homologous recombination (HR) genes (e.g., BRCA1/2) or HRD scores. Instead, we found several proteomic markers that predicted PDX response, including high levels of SLFN11 and E-cadherin and low ATM. SLFN11 and E-cadherin were also significantly associated with in vitro sensitivity to cisplatin and topoisomerase1/2 inhibitors (all commonly used in SCLC). Treatment with cisplatin or PARP inhibitors downregulated SLFN11 and E-cadherin, possibly explaining the rapid development of therapeutic resistance in SCLC. Supporting their functional role, silencing SLFN11 reduced in vitro sensitivity and drug-induced DNA damage; whereas ATM knockdown or pharmacologic inhibition enhanced sensitivity. Notably, SCLC with mesenchymal phenotypes (i.e., loss of E-cadherin and high epithelial-to-mesenchymal transition (EMT) signature scores) displayed striking alterations in expression of miR200 family and key SCLC genes (e.g., NEUROD1, ASCL1, ALDH1A1, MYCL1). Thus, SLFN11, EMT, and ATM mediate therapeutic response in SCLC and warrant further clinical investigation as predictive biomarkers.

Original languageEnglish
Pages (from-to)28575-28587
Number of pages13
JournalOncotarget
Volume8
Issue number17
DOIs
StatePublished - 2017
Externally publishedYes

Keywords

  • ATM
  • EMT
  • PARP inhibitor
  • SCLC
  • SLFN11

Fingerprint

Dive into the research topics of 'Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer'. Together they form a unique fingerprint.

Cite this